AWAlicia Ac Waite

Alicia Ac Waite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alicia Ac Waite has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew J Boyle

    Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK

    3 shared publications
  • Brian W Johnston

    Intensive Care Unit, Royal Liverpool University Hospital, Liverpool, UK

    3 shared publications
  • Christina Jones

    ICUsteps Charity, London, UK

    3 shared publications
  • Ingeborg D Welters

    Intensive Care Unit, Royal Liverpool University Hospital, Liverpool, UK

    3 shared publications
  • Karen Williams

    Intensive Care Unit, Royal Liverpool University Hospital, Liverpool, UK

    3 shared publications
  • Mary Gemma Cherry

    Department of Primary Care and Mental health, Institute of Population Health, University of Liverpool, Liverpool, UK

    3 shared publications

Latest Publications

  • Identification of difficult airways in critical care units (ID-ACCT): a multicentre, survey-based prospective observational study

    by Thomas J. McClelland, Adam J. Boulton, Alicia A.C. Waite, Andrew J. Boyle, Luke Flower, Amy Nash, Daniel Wagstaff, Brian W. Johnston, Luke Austen, Alexander Butcher, et al.


  • Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza

    by Alicia A C Waite, Leon Peto, Anthony C Gordon, Peter Horby

    Evidence-based effective treatments for hospitalized patients with influenza have yet to be identified. Traditional randomized controlled trials have struggled to provide definitive guidance due in part to small sample sizes and logistical challenges. Adaptive platform trials, such as REMAP-CAP (Randomised Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) and RECOVERY (Randomised Evaluation of COVID-19 Therapy), offer a transformative approach to evaluating influenza therapeutics. REMAP-CAP and RECOVERY utilize flexible, efficient designs that enable the simultaneous assessment of multiple interventions, adaptation to emerging data, and large-scale recruitment. Both platforms are currently evaluating antiviral and immunomodulatory therapies for severe influenza, building on their success in identifying effective treatments for COVID-19. Establishing global platform trials for influenza will facilitate the generation of high-quality evidence to guide seasonal influenza treatment and enhance pandemic preparedness. A coordinated international effort to sustain platform trials beyond pandemic periods is essential for improving clinical outcomes, optimizing resource utilization, and ensuring readiness for future pandemics.


  • Provision of follow-up services for survivors of COVID-19 critical illness: A UK national survey

    by Jin-Xi Yuan, Constance E D Osborne, Ibrahim Almafreji, Bronwen Connolly, Andrew J Boyle, Mary Gemma Cherry, Brian W Johnston, Karen Williams, Christina Jones, Peter Fisher, et al.

    Background: Intensive care unit (ICU) survivors in the United Kingdom (UK) can receive support from ICU follow-up services in their process of recovery and rehabilitation. However, it is unclear whether the COVID-19 pandemic impacted the ability of UK hospitals to provide follow-up. The objective of this study was to evaluate the provision of follow-up services in the UK for adult survivors of COVID-19 critical illness. Methods: All adult National Health Service (NHS) ICUs in the UK were invited to participate. Intensive care clinicians aware of follow-up services offered at their site were invited to complete a self-administered online electronic survey. Free text answers were thematically analysed. Results: 174 of 242 (71.9%) NHS hospitals responded to the survey. 140 (80.5%) of the respondent hospitals had an ICU follow-up service for survivors of COVID-19 critical illness. A new service was created at 28 (16.1%) hospitals during the COVID-19 pandemic. ICU follow-up services were mostly delivered by nurses (125/140, 89.3%), ICU doctors (111/140, 79.3%), physiotherapists (88/140, 62.9%) and psychologists (59/140, 42.1%). Where ICU follow-up services already existed, changes were made in 111 (79.3%) hospitals during the pandemic and these were maintained in 89 (80.2%) hospitals. Funding was a commonly reported reason for whether follow-up services were offered. Conclusions: There was an expansion in the number of ICU follow-up clinics, and the multidisciplinary team delivering post-ICU care to patients who survived COVID-19 critical illness. Many changes to clinic operations introduced during the pandemic persisted, including the use of virtual and hybrid follow-up clinic models.


  • Psychological impact of an intensive care admission for COVID-19 on patients in the United Kingdom

    by Alicia Ac Waite, Mary Gemma Cherry, Stephen L Brown, Karen Williams, Andrew J Boyle, Brian W Johnston, Christina Jones, Peter Fisher, Ingeborg D Welters

    Background: The psychological impact of surviving an admission to an intensive care unit (ICU) with COVID-19 is uncertain. The objective of the study was to assess the prevalence of anxiety, depression and post-traumatic stress disorder (PTSD) symptoms in ICU survivors treated for COVID-19 infection, and identify risk factors for psychological distress. Methods: This observational study was conducted at 52 ICUs in the United Kingdom. Participants, treated for COVID-19 infection during an ICU admission of ⩾24 h, were recruited post-ICU discharge. Self-report questionnaires were completed at 3, 6 and/or 12 months. Symptoms of anxiety and depression were identified using the Hospital Anxiety and Depression Scale. PTSD was assessed using the Impact of Events Scale-6. Demographic, clinical, physical and psychosocial factors were considered as putative predictors of psychological distress. Results: 1620 patients provided consent and 1258 (77.7%) responded to at least one questionnaire, with responses at 3 months ( N = 426), 6 months ( N = 656) and 12 months ( N = 1050) following ICU admission. The following prevalence rates were found at 3, 6 and 12 months, respectively: anxiety in 28.8% (95% CI 24.6–33.1), 30.4% (95% CI 27.0–33.8) and 29.3% (95% CI 26.5–32.1); depression in 25.1% (21.0–29.3), 25.9% (22.7–29.3) and 24.0% (21.5–26.6); and PTSD in 43.5% (38.8–48.2), 44.3% (40.6–48.0) and 43.2% (40.2–46.1) of patients. Risk factors for psychological distress included a previous mental health diagnosis, unemployment or being on sick leave, and a history of asthma or COPD. Conclusion: Clinically significant symptoms of anxiety, depression and PTSD were common and persisted up to 12 months post-ICU discharge.


  • Open Access

    PIM-COVID study: protocol for a multicentre, longitudinal study measuring the psychological impact of surviving an intensive care admission due to COVID-19 on patients in the UK

    by Alicia A C Waite, Brian W Johnston, Andrew J Boyle, Mary Gemma Cherry, Peter Fisher, Stephen L Brown, Christina Jones, Karen Williams, Ingeborg D Welters

    Introduction Psychological distress is common in intensive care unit (ICU) survivors and is anticipated in those who were treated for severe COVID-19 infection. This trainee-led, multicentre, observational, longitudinal study aims to assess the psychological outcomes of ICU survivors treated for COVID-19 infection in the UK at 3, 6 and/or 12 months after ICU discharge and explore whether there are demographic, psychosocial and clinical risk factors for psychological distress. Methods and analysis Questionnaires will be provided to study participants 3, 6 and/or 12 months after discharge from intensive care, assessing for anxiety, depression, post-traumatic stress symptoms, health-related quality of life and physical symptoms. Demographic, psychosocial and clinical data will also be collected to explore risk factors for psychological distress using latent growth curve modelling. Study participants will be eligible to complete questionnaires at any of the three time points online, by telephone or by post. Ethics and dissemination The PIM-COVID study was approved by the Health Research Authority (East Midlands - Derby Research and Ethics Committee, reference: 20/EM/0247). Trial registration number NCT05092529.


  • Is your study acronym someone else’s intellectual property?

    by Alicia Ac Waite, Heather Rogers, Sandra Winskill, Ingeborg D Welters